Accelr8 Announces Industry Agreement for Technology Evaluation Project
17 June 2010 - 10:00PM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) today
announced that it signed a technology evaluation agreement for its
BACcel™ rapid diagnostic system with a global diagnostics company.
The short-term agreement includes an option for a license to
complete product development, obtain regulatory approvals, and
produce and market innovative diagnostic products based on the
technology in global markets. The agreement calls for an initial
payment plus scheduled payments of additional funds until
completion of data evaluation.
The project incorporates analysis of data being collected in
pre-clinical and pilot studies already initiated at the Denver
Health Medical Center, and at the Barnes-Jewish Hospital in St.
Louis (the Washington University in St. Louis School of Medicine).
In addition, Accelr8 will share data and materials related to its
ongoing development of advanced tests for antibiotic resistance
detection.
The company also released results from its presentation at the
annual General Meeting of the American Society for Microbiology
(ASM) in San Diego on May 24. The study was co-authored by
principal investigators at Denver Health, Barnes-Jewish, and
Accelr8. The investigators performed quantitative identification of
three major “superbug” species and strains added to respiratory
specimens from ICU patients. The study addressed the three major
species that cause about half of serious hospital-acquired
infections (HAI) and are prone to acquire multiple mechanisms of
antibiotic resistance. The 2-hour test, directly from specimen,
achieved quantitative accuracy equal to that of the standard
culture reference method. Identification sensitivity and
specificity ranged from 90% to 100% with different organisms.
The company further announced its acceptance to present another
new study in September at the 50th ICAAC (Interscience Conference
for Antimicrobial Agents and Chemotherapy, www.icaac.org).
According to David Howson, Accelr8’s president, “We are very
pleased to have a global industry leader evaluate our technology
with the intent to commercialize it. This level of interest helps
to validate our choice of markets for our breakthrough technology
platform. The studies already started at our two collaborating
institutions will integrate smoothly into the new plan. The funding
is sufficient to achieve the project objectives.
“At this year’s ASM,” Howson continued, “we confirmed the
continuing lack of any competing technology. Unlike other new
technologies that only identify organisms, or only detect two or
three resistance types, our system detects all of the organisms and
resistance types that most often cause therapy to fail. Our data
once again set a new standard for same-day, culture-free analysis
of the most dangerous pathogens. The complex materials in real
specimens can powerfully interfere with direct, culture-free
analysis, and we’ve overcome that critical hurdle.
“We will now advance our tests over the next eight months to
detect highly threatening new types of resistance that defeat
standard laboratory tests. These tests use sophisticated analyses
that are also valuable for new drug development. We’re
demonstrating with hard data the potential to uniquely address the
antibiotic resistance crisis that confronts the healthcare system
with ‘unsustainable’ demands, according to leading
epidemiologists,” he concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications
in medical instrumentation, basic research, drug discovery, and
bio-detection. Accelr8 is developing a rapid analytical platform
for infectious pathogens, the BACcel™ system, based on its
innovative surface coatings, assay processing, and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024
